CN1626653A - 用于分离组织的中性蛋白酶（np）和使用中性蛋白酶的制品及其制备方法 - Google Patents
用于分离组织的中性蛋白酶（np）和使用中性蛋白酶的制品及其制备方法 Download PDFInfo
- Publication number
- CN1626653A CN1626653A CNA2004101005333A CN200410100533A CN1626653A CN 1626653 A CN1626653 A CN 1626653A CN A2004101005333 A CNA2004101005333 A CN A2004101005333A CN 200410100533 A CN200410100533 A CN 200410100533A CN 1626653 A CN1626653 A CN 1626653A
- Authority
- CN
- China
- Prior art keywords
- collagenase
- neutral protease
- component
- tissue
- pancreas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000145 Bacillolysin Proteins 0.000 title claims abstract description 111
- 102000035092 Neutral proteases Human genes 0.000 title claims abstract description 111
- 108091005507 Neutral proteases Proteins 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims description 27
- 238000010494 dissociation reaction Methods 0.000 title abstract 2
- 230000005593 dissociations Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 108060005980 Collagenase Proteins 0.000 claims abstract description 72
- 102000029816 Collagenase Human genes 0.000 claims abstract description 72
- 229960002424 collagenase Drugs 0.000 claims abstract description 70
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 230000035899 viability Effects 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims description 21
- 238000003860 storage Methods 0.000 claims description 13
- 241000193159 Hathewaya histolytica Species 0.000 claims description 12
- 241001232809 Chorista Species 0.000 claims description 11
- 102000035195 Peptidases Human genes 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 230000008521 reorganization Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 238000002955 isolation Methods 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 description 92
- 102000004190 Enzymes Human genes 0.000 description 36
- 108090000790 Enzymes Proteins 0.000 description 36
- 229940088598 enzyme Drugs 0.000 description 35
- 210000004153 islets of langerhan Anatomy 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 239000000203 mixture Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 210000000056 organ Anatomy 0.000 description 13
- 238000000926 separation method Methods 0.000 description 12
- 108010052014 Liberase Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000003366 colagenolytic effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- -1 tetrazole compound Chemical class 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 108090001092 clostripain Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000012803 optimization experiment Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710119640 Trypsin-4 Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000000597 exocrine pancreas cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021191 food habits Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10331171.8 | 2003-07-09 | ||
| DE10331171A DE10331171A1 (de) | 2003-07-09 | 2003-07-09 | Neutrale Protease (NP) und Produkt unter Verwendung von neutraler Protease für Gewebedissoziation sowie Verfahren zu dessen Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1626653A true CN1626653A (zh) | 2005-06-15 |
Family
ID=33441697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004101005333A Pending CN1626653A (zh) | 2003-07-09 | 2004-06-17 | 用于分离组织的中性蛋白酶（np）和使用中性蛋白酶的制品及其制备方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8440445B2 (https=) |
| EP (1) | EP1496112B1 (https=) |
| JP (3) | JP2005046136A (https=) |
| CN (1) | CN1626653A (https=) |
| AT (1) | ATE471979T1 (https=) |
| BR (1) | BRPI0402615B1 (https=) |
| CA (1) | CA2469137C (https=) |
| DE (2) | DE10331171A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010105820A1 (en) * | 2009-03-19 | 2010-09-23 | Roche Diagnostics Gmbh | Improved blends containing proteases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4408940A1 (de) | 1994-03-16 | 1995-10-05 | Boehringer Mannheim Gmbh | Rekombinante Collagenase Typ II aus Clostridium histolyticum und ihre Verwendung zur Isolierung von Zellen und Zellverbänden |
| CA2189646C (en) * | 1994-06-24 | 1999-05-25 | Francis E. Dwulet | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
| DE4445891A1 (de) * | 1994-12-22 | 1996-06-27 | Boehringer Mannheim Gmbh | Rekombinante Proteinase aus Clostridium histolyticum und ihre Verwendung zur Isolierung von Zellen und Zellverbänden |
| US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| ATE272109T1 (de) * | 1996-11-19 | 2004-08-15 | Roche Diagnostics Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| ATE302844T1 (de) | 2001-07-02 | 2005-09-15 | Nordmark Arzneimittel Gmbh & C | Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms |
-
2003
- 2003-07-09 DE DE10331171A patent/DE10331171A1/de not_active Withdrawn
-
2004
- 2004-05-25 EP EP04012321A patent/EP1496112B1/de not_active Expired - Lifetime
- 2004-05-25 AT AT04012321T patent/ATE471979T1/de active
- 2004-05-25 DE DE502004011298T patent/DE502004011298D1/de not_active Expired - Lifetime
- 2004-06-16 US US10/869,313 patent/US8440445B2/en not_active Expired - Fee Related
- 2004-06-17 CN CNA2004101005333A patent/CN1626653A/zh active Pending
- 2004-06-18 JP JP2004181373A patent/JP2005046136A/ja active Pending
- 2004-06-22 CA CA2469137A patent/CA2469137C/en not_active Expired - Fee Related
- 2004-07-08 BR BRPI0402615-2A patent/BRPI0402615B1/pt not_active IP Right Cessation
-
2010
- 2010-01-14 JP JP2010005801A patent/JP2010081941A/ja active Pending
-
2011
- 2011-05-02 JP JP2011102735A patent/JP2011147458A/ja not_active Withdrawn
-
2013
- 2013-04-15 US US13/862,773 patent/US8765471B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050142632A1 (en) | 2005-06-30 |
| ATE471979T1 (de) | 2010-07-15 |
| EP1496112A3 (de) | 2005-10-12 |
| DE10331171A1 (de) | 2005-01-27 |
| JP2005046136A (ja) | 2005-02-24 |
| US8765471B2 (en) | 2014-07-01 |
| EP1496112A2 (de) | 2005-01-12 |
| BRPI0402615A (pt) | 2005-06-28 |
| CA2469137C (en) | 2015-11-24 |
| CA2469137A1 (en) | 2005-01-09 |
| US20130230922A1 (en) | 2013-09-05 |
| BRPI0402615B1 (pt) | 2017-07-04 |
| JP2010081941A (ja) | 2010-04-15 |
| US8440445B2 (en) | 2013-05-14 |
| JP2011147458A (ja) | 2011-08-04 |
| DE502004011298D1 (de) | 2010-08-05 |
| EP1496112B1 (de) | 2010-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506047A (ja) | インスリン産生細胞のための方法、成分並びに成長および分化因子 | |
| Giovagnoli et al. | Long-term delivery of superoxide dismutase and catalase entrapped in poly (lactide-co-glycolide) microspheres: in vitro effects on isolated neonatal porcine pancreatic cell clusters | |
| Wang et al. | Molecular characterization and expression profiles of insulin-like growth factors in yellowtail kingfish (Seriola lalandi) during embryonic development | |
| CN109715806B (zh) | 解除有用虾类的卵成熟抑制的方法 | |
| Zeng et al. | Transcriptome analysis and identification of genes and single‐nucleotide polymorphisms associated with growth traits in the Chinese soft‐shelled turtle, Pelodiscus sinensis | |
| CN1303103C (zh) | 膜透过型nfat抑制肽 | |
| CN1626653A (zh) | 用于分离组织的中性蛋白酶（np）和使用中性蛋白酶的制品及其制备方法 | |
| Kiemnec-Tyburczy et al. | Evolutionary shifts in courtship pheromone composition revealed by EST analysis of plethodontid salamander mental glands | |
| Huang et al. | The physiological implications of dietary high-amylose starch on the growth performance, hepatic health indices, lipid metabolism, and intestinal microbiota composition in largemouth bass (Micropterus salmoides) | |
| CN100526455C (zh) | 用于体外分离和培养具有种系传递能力的胚胎干细胞(es)细胞系的组合物 | |
| US12545895B2 (en) | Protection of beta cells from immune attack | |
| Gao et al. | Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice | |
| CN1854288A (zh) | 可高产糖肽复合物的灵芝真菌及其诱变选育方法和用途 | |
| EP3217785B1 (en) | Functional sex-reversal of decapod crustacean females | |
| CN1926234A (zh) | 使用nm23的细胞培养,包含nm23的细胞培养基和在nm23存在下培养的细胞的治疗性用途 | |
| CN1871342A (zh) | p18对干细胞的调控 | |
| CA2613849C (en) | Use of human growth hormone in mouse carrying human hepatocytes | |
| CN104650184B (zh) | 一种突变的tbc1d1蛋白信号分子及其应用 | |
| RU2846197C1 (ru) | Универсальные донорские клетки и связанные с ними способы | |
| US20250276014A1 (en) | Genetically engineered innate lymphoid cells for enhancing lifespan and/or treating cancers | |
| García Eusebi et al. | Genetic diversity analysis of the Mexican Lidia bovine breed population and its relation with the Spanish population by using a subset of SNPs under low gametic disequilibrium | |
| Piollet et al. | Neutrophil terminal programming in the ischemic heart drives fibrosis after myocardial infarction | |
| Ulrichs | Pancreatic islet transplantation: Factors that determine insufficient long-term function and strategies to overcome such limitations | |
| WO2023183953A1 (en) | Delivery of dissociated islets cells within microporous annealed particle scaffold to treat type 1 diabetes | |
| KR20250043117A (ko) | Bmp10을 이용한 소장 재생 모사 오가노이드 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |